The Grange Biology Forum

An open forum for members of the Grange Biology community to exchange ideas and information
HomeCalendarFAQSearchMemberlistUsergroupsRegisterLog in


 Anti-tumor necrosis factor in the treatment of inflammatory rheumatic diseases

Go down 

Posts : 50
Join date : 2012-03-30

Anti-tumor necrosis factor in the treatment of inflammatory rheumatic diseases Empty
PostSubject: Anti-tumor necrosis factor in the treatment of inflammatory rheumatic diseases   Anti-tumor necrosis factor in the treatment of inflammatory rheumatic diseases Icon_minitimeSun Jul 01, 2012 10:43 pm

A meta-analysis from the 2012 European League Against Rheumatism: Compared with the LRRTM4 conventional alleviate disease modifying antirheumatic drug treatment programs, using up to 75% risk of anti-TNF treatment of inflammatory rheumatic disease patients infected with the herpes virus. The "conventional alleviate disease modifying antirheumatic drugs can not effectively control the disease, including infliximab, adalimumab, in accordance with etanercept, including anti-tumor LSD1 necrosis factor drugs to continue treatment, are the original kind of adverse drug reactions bacterial infection, an increased risk. "the person in charge of the study, from France Lapeyronie hospital of Helene Ms. pointed out.This review surveys and meta-analysis suggests the need for anti-tumor necrosis factor therapy in patients with close monitoring of patients with herpes zoster early signs and LSM1 symptoms, and when the vaccine-preventable virus infection on the agenda.

The researchers did a literature search of the Medline database from 2006 to 2010, the Cochrane library, American College of Rheumatology and European League Against Rheumatism abstracts. Registration of the 657 papers, 134 abstracts and 11 family files, 22 articles and 28 abstracts met the LSM4 inclusion criteria were included in the study. Meta-analysis included a total of 124,966 person-years of follow-up (74,198 person-years in the biological agents group, 50,768 person-years in conventional remission of disease-modifying antirheumatic drug group). Occurrence of herpes zoster cases were included in the meta-analysis of anti-tumor necrosis factor treatment and conventional LSP1 treatment process.Severe herpes virus infections, including multiple skin lesions, hospitalization or intravenous drug therapy were excluded. Shingles is caused by the varicella zoster virus skin pain herpes, the virus can cause chickenpox. More than 60 years old, suffering from chicken pox before the age as well as due to drugs or disease caused by immunocompromised people more susceptible to herpes zoster. Symptoms include a burning sting of the small papules and the side of the midline of the body followed by the final rupture, dry scab herpes. Other symptoms include chills, fever, abdominal pain, swollen glands, facial muscle movement is limited, and ptosis. Usually the use of antiviral drugs to reduce pain and complications. Hormones to relieve swelling. Although the infection usually lasts 2-3 weeks, but the pain is often persist for several months to several years. Virus infection can lead to temporary or permanent paralysis.
Back to top Go down
View user profile
Anti-tumor necrosis factor in the treatment of inflammatory rheumatic diseases
Back to top 
Page 1 of 1
 Similar topics
» Anti-vacuum valve - slight drip
» New treatment direction

Permissions in this forum:You cannot reply to topics in this forum
The Grange Biology Forum :: MIKE FARRANT :: 3rd Medio AS :: Anti-Smoking Advertising (MFA)-
Jump to: